Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
about
Mpl traffics to the cell surface through conventional and unconventional routesJAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatinKinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitorsSignal transduction in the chronic leukemias: implications for targeted therapiesTranscriptional profiling of the dose response: a more powerful approach for characterizing drug activitiesTyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B betaAHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cellsIcaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalingsAHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.c-Abl activates janus kinase 2 in normal hematopoietic cells.A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML)JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.Jak2 is involved in c-Myc induction by Bcr-Abl.BCR-ABL as a target for novel therapeutic interventions.Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.Advances in targeted therapy for chronic myeloid leukemia.Ebf1 or Pax5 haploinsufficiency synergizes with STAT5 activation to initiate acute lymphoblastic leukemia.Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.STAT5 gene polymorphisms are associated with the response of acute myeloid leukemia patients to Ara-C-based chemotherapy.JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growthC/EBPβ promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersSOCS2 is dispensable for BCR/ABL1-induced chronic myeloid leukemia-like disease and for normal hematopoietic stem cell function.Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).Targeting survival pathways in chronic myeloid leukaemia stem cellsJAK mutations in high-risk childhood acute lymphoblastic leukemiaBM microenvironmental protection of CML cells from imatinib through Stat5/NF-κB signaling and reversal by Wogonin.Following the cytokine signaling pathway to leukemogenesis: a chronologySignaling networks associated with BCR-ABL-dependent transformation.Fine-tuning patient-derived xenograft models for precision medicine approaches in leukemia.CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.In search of CML stem cells' deadly weakness.Kinase activation in circulating cells: opportunities for biomarkers for diagnosis and therapeutic monitoring.
P2860
Q24299221-B812C7C5-BF7B-4478-94C6-392D70AE84C7Q24318979-3775651A-AC21-49B3-94C4-3CAF14515668Q26849792-4A3F6A3F-941E-4AAB-A930-4A55181D35D1Q27026031-165C3CE6-2AEB-4472-B1C5-26C91A5FF03AQ28476104-B394D50D-454D-4B49-9A72-CAF497B7A029Q28506708-BBD6741C-2587-4A1F-8AFB-3C08AE083D8DQ28586026-757CD990-02F2-4BD0-8567-22F584E4BE5EQ28741022-EC9ECCCE-CDD9-4F11-9F09-5B7A36E18641Q30010179-6832E47B-C767-4EB9-8402-E90B91718676Q30159676-75789384-77F5-4E0B-B069-ABFA972F4C77Q30165112-4B1F4CF0-6F20-4DE2-B775-23CC4D508A9EQ33985308-8070C0DB-8777-4F82-8EAE-A9FE897EF077Q34065882-FA2ABF83-EE1B-4874-B8EF-AD490FBB32D6Q34082540-8141A4BC-12B6-47CF-A4AB-277E7346B9AFQ34106870-3422EA8C-05FC-49D8-8337-BC3E7EEC033FQ34153616-766C403C-9F38-459E-843B-1AA2003D96FAQ34568971-BA769920-5A79-4C68-A036-FAB16F5CF2E3Q34718163-42476C9D-C68D-49D9-9D02-4C5B9633DBADQ34771074-770703CB-DB21-4D7B-9D62-1461328CFB70Q35160190-7FF0507D-A0F7-44FC-B334-07659385BBCBQ35213566-6B525705-4990-4617-BAE1-6BF32B338546Q35583420-2BF35751-D1E2-425B-9A60-1D2A26352FDCQ35780557-C78FC377-0C2F-41AE-9877-E160D2ACBBE7Q35861885-9806693F-3511-4E73-B073-B13F8E1E2FB8Q35864103-FA1EADED-7E32-4A63-AE47-CF1AA3322BA6Q35931271-9F0DB29C-83EF-44DC-8940-ED7646D9581FQ36088198-BF39BCE2-42E8-4747-A9F5-3840DB88440FQ36316166-6309AEBE-684A-490B-A174-F882570E8677Q36374813-9AD046C5-8298-4E2A-BB51-E601FF58B58BQ36525983-2EE0D95F-BA0B-4DF6-BEB7-1B0CEE766966Q36822880-4B3C3ACB-C4CE-409D-B239-1DBE3B619FEEQ37122686-456807C5-0FEF-4743-8FEB-2396EE004B63Q37224111-17B82742-6EB7-446F-8129-82841E9F7EB0Q37269332-815884FA-53C7-4C20-8310-1BC68A3C652EQ37316601-357EE155-B16F-42FC-ABB5-3B1251897A28Q37428655-D52B84D8-BEBA-4FA0-B3A8-9F4C540DE55FQ37500159-C299448D-D686-404E-A23C-F15C76F43699Q37638846-5E7F65D2-9A50-49B0-814C-7C8B423E3696Q37849628-E42906E6-72E9-417A-93DC-03ABECB97F76Q38088832-CF3A30B9-0449-47D6-87A7-DE048BD97196
P2860
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@ast
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@en
type
label
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@ast
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@en
prefLabel
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@ast
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@en
P2093
P356
P1433
P1476
Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation.
@en
P2093
Arlinghaus RB
Smithgall TE
P2888
P304
P356
10.1038/SJ.ONC.1204834
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1008994674